Incyclix Bio
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
600 Park Offices Dr Ste 355, Durham, Nor...Phone Number
(919) 328-0003Website
www.incyclixbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Incyclix Bio
Incyclix Bio is a clinical-stage biotechnology company focused on precision oncology, developing selective CDK2 inhibitorslike INX315to treat advanced and treatment-resistant cancers by targeting dysregulated cell cycle pathways.Explore more
Incyclix Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Incyclix Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Incyclix Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Incyclix Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Incyclix Bio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Incyclix Bio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Incyclix Bio has new funding data
Click to see if Incyclix Bio had a recent Job posting/layoffs
Earning: See what the market has to say on Incyclix Bio recently announced quarterly report
Product Launch: Get notified when Incyclix Bio launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Incyclix Bio
Compare insights from companies similar to Incyclix Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Incyclix Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Incyclix Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Incyclix Bio.
Incyclix Bio financials insights
Gather financial insights about Incyclix Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$11.3M
Series B
$41M
2026
Unspecified
$5M
Incyclix Bio Tech Stack
A closer look at the technologies used by Incyclix Bio
Most Recent Scoops
Funding
Funding
Funding
Funding
Project
Product Development, Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Partnership
Partnership, Research & Development, Logistics / Supply Chain, Medical Research, Pharmaceuticals, Clinical Operations
Funding
Incyclix Bio News & Media
Incyclix Bio's Hope: A Surging $5M for Cancer Trial
Incyclix Bio secured an additional $5 million extension to its Series B from Hatteras Venture Partners to advance INX-315, a selective CDK2 inhibitor now in an ongoing Phase 1/2 dose-escalation and expansion study in recurrent advanced or metastatic cancers, with a focus on breast and ovarian settings. The capital comes alongside board changes and addsIncyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
Additional $5 million from Hatteras Venture Partners supports advancement of Phase 1/2 clinical trial of INX-315 in patients with recurrent advanced/metastatic cancer Additional $5 million from Hatteras Venture Partners supports advancement of Phase 1/2 clinical trial of INX-315 in patients with recurrent advanced/metastatic cancerIncyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced the appointment of Kimberly Blackwell, MD, to its Board of Directors as an independent board member. Dr. Blackwell is a leading oncology innovator and breast cancer researcher who brings over 20 years in drug development experience toFierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025
RESEARCH TRIANGLE PARK, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, today announced that Fierce Biotech has named it as one of 2025’s Fierce 15 biotechnology companies, designating it as one of the most innovative and promising private biotechnology companies in the industry.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Incyclix Bio
Sign Up For FreeTo access detailed company insights
Incyclix Bio is a clinical-stage biotechnology company focused on precision oncology, developing selective CDK2 inhibitorslike INX315to treat advanced and treatment-resistant cancers by targeting dysregulated cell cycle pathways.... Read More
